Multidimensional regulatory roles and therapeutic applications of SRSF7 in cancer

Yuan Li1, Huimeng Gao1, Xuanyu Zhang1

  • 1Department of Oral Biology, School and Hospital of Stomatology, China Medical University, Liaoning Province Key Laboratory of Oral Disease, Shenyang, Liaoning, 110002, China.

Cell Death Discovery
|December 30, 2025
PubMed

Insights

Serine/Arginine-rich Splicing Factor 7 (SRSF7) is crucial in cancer development and progression. Understanding SRSF7

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Malignant tumors are a leading cause of mortality worldwide.
  • Serine/Arginine-rich Splicing Factor 7 (SRSF7) is a key splicing regulator implicated in various cancers.
  • Aberrant SRSF7 expression is observed in lung, colorectal, liver, and oral cancers.

Purpose of the Study:

  • To review the molecular mechanisms of SRSF7 in tumorigenesis.
  • To focus on SRSF7's role in epigenetic reprogramming within tumors.
  • To explore SRSF7's involvement in cancer progression, immune evasion, and therapeutic resistance.

Main Methods:

  • Literature review of studies on SRSF7 function in cancer.
  • Analysis of SRSF7's role in cell cycle regulation, non-coding RNA, RNA methylation, and glucose metabolism.
  • Examination of SRSF7's impact on the tumor immune microenvironment and immune checkpoint PD-1.

Main Results:

  • SRSF7 influences epigenetic reprogramming, cell cycle control, non-coding RNA, RNA methylation, and glucose metabolism in tumors.
  • SRSF7 contributes to immune evasion via alternative splicing and PD-1 immune checkpoint.
  • SRSF7 family members play a role in tumor resistance, including chemoresistance, through alternative splicing.

Conclusions:

  • SRSF7 is a significant factor in tumorigenesis and cancer progression.
  • SRSF7 presents potential as a target for tumor intervention therapies and companion diagnostics.
  • Further experimental and clinical studies are necessary to validate SRSF7's clinical applications.

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.1K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.6K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K